Hit-to-lead evolution of 2-(2-((2-(4-chlorophenoxy) ethyl) thio)-1H-benzo [d] imidazol-1-yl) acetic acid (1), discovered in a high-throughput screening campaign as a novel chemotype of CRTh2 receptor antagonist, is presented. SAR development as well as in vitro and in vivo DMPK properties of selected representatives of substituted 2-(2-(benzylthio)-1H-benzo [d] imidazol-1-yl) acetic acids are discussed.